Core Viewpoint - DJS Law Group is investigating claims against RxSight, Inc. for potential violations of securities laws related to misleading statements and undisclosed information impacting investors [1][2]. Investigation Details - The investigation centers on RxSight's financial performance, particularly the decline in sales of Light Delivery Devices (LDD) and total revenue [2]. - RxSight reported a significant drop in key metrics and lowered its full-year financial guidance, attributing the changes to "adoption challenges" leading to an "LDD stall" [2]. - Following the financial report, RxSight's shares plummeted by nearly 38% on the announcement day [2].

LOS ANGELES, July 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 7, 2024 and July 8, 2025, inclusive (the "Class Period"), are enc ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025. SO WHAT: If you purchased RxSight securities during the Class P ...

Core Insights - RxSight, Inc. will report its financial results for Q2 2025 on August 7, 2025, after market close [1] - A conference call to discuss the results will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - RxSight, Inc. specializes in ophthalmic medical devices, focusing on customized vision solutions for patients post-cataract surgery [3] - The company offers the RxSight® Light Adjustable Lens system, which is the first and only intraocular lens technology that can be adjusted after surgery [3] - This technology allows doctors to provide tailored high-quality vision to patients following cataract procedures [3] Contact Information - Chief Financial Officer: Shelley B. Thunen, Email: sthunen@rxsight.com [4] - VP, Investor Relations: Oliver Moravcevic, Email: omoravcevic@rxsight.com [4]

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired RxSight securiti ...

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified class period [1][2]. Company Overview - RxSight, Inc. is a medical technology company based in Aliso Viejo, CA, specializing in light adjustable intraocular lenses (LAL) used in cataract surgery, with its system involving the Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the sales stall to adoption challenges over recent quarters [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell another 38% from $12.79 to $7.95 per share [6].

Core Viewpoint - A securities class action lawsuit has been filed against RxSight, Inc. for failing to disclose significant operational challenges and misleading investors regarding the company's financial outlook [1][2]. Group 1: Allegations Against the Company - The lawsuit alleges that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is claimed that the company overstated the demand for its products, which contributed to an inability to meet previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the company regarding its business operations and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Financial Impact - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue [3]. - Following this announcement, the company's stock price dropped by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [3].

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false statements and failing to disclose significant issues affecting its sales and financial guidance during the specified class period [1][2][3]. Summary by Sections Class Action Lawsuit - The lawsuit is on behalf of all individuals and entities who purchased RxSight securities between November 7, 2024, and July 8, 2025, with a deadline of September 22, 2025, for investors to apply as lead plaintiffs [1]. - Allegations include that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization, and that the demand for its products was overstated [2]. Financial Performance - On July 8, 2025, RxSight reported preliminary second-quarter financial results showing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [3]. - The company lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint, attributing the decline to adoption challenges [3]. - Following this announcement, RxSight's stock price fell nearly 38% [3].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines following the disclosure of poor financial results [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of poor financial results led to a nearly 38% drop in the price of RxSight stock [5].